Faruqi and Faruqui, LLP Logo
Share this page

In re Skelaxin (Metaxalone) Antitrust Litigation, No. 12-MD-2343 (E.D. Tenn.)

Summary

In this case, nicknamed Skelaxin, Faruqi & Faruqi, LLP represented a pharmaceutical wholesaler and a class of direct purchasers of the muscle relaxant drug Skelaxin (metaxalone), which has been on the market, without generic competition, since the 1960s. The suit alleged that the brand manufacturer (King) and a generic drug company (Mutual), conspired to delay generic competition until 2010, in violation of §§ 1 and 2 of the Sherman Act. As a result of the alleged scheme, the suit alleged, class members incurred overcharge damages in the hundreds of millions of dollars. A settlement of $73 million was reached in late 2013 with Defendants and was finally approved by the court on September 24, 2014.

Contact Counsel

Joseph T. Lukens
Peter Kohn
Faruqi & Faruqi, LLP
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Tel: (215) 277-5770

Email:

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.